MediWound (MDWD) Projected to Release Earnings on Thursday

MediWound (NASDAQ:MDWD) is anticipated to post its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.76) per share and revenue of $2.5890 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:30 AM ET.

MediWound (NASDAQ:MDWD) last posted its earnings results on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.42. The business had revenue of $1.48 million during the quarter, compared to analyst estimates of $3.37 million. MediWound had a negative return on equity of 67.22% and a negative net margin of 180.30%.During the same quarter last year, the company earned ($0.07) EPS. On average, analysts expect MediWound to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MediWound Price Performance

Shares of NASDAQ:MDWD opened at $13.83 on Tuesday. MediWound has a 1 year low of $13.54 and a 1 year high of $20.30. The company has a market cap of $177.72 million, a P/E ratio of -6.12 and a beta of 0.15. The stock’s fifty day moving average price is $14.38 and its 200-day moving average price is $16.06.

Insider Buying and Selling at MediWound

In other news, Director David Morton Fox bought 3,537 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was bought at an average price of $14.11 per share, with a total value of $49,907.07. Following the acquisition, the director owned 22,283 shares of the company’s stock, valued at approximately $314,413.13. This represents a 18.87% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On MediWound

Several large investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of MediWound by 22.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares in the last quarter. Rhumbline Advisers lifted its holdings in MediWound by 4.4% in the 1st quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 481 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in MediWound by 69.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 649 shares during the period. Marshall Wace LLP purchased a new stake in MediWound during the 2nd quarter valued at approximately $317,000. Finally, The Manufacturers Life Insurance Company grew its holdings in MediWound by 104.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,062 shares of the biopharmaceutical company’s stock valued at $505,000 after buying an additional 13,312 shares in the last quarter. 46.83% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a report on Friday, July 17th. Wall Street Zen raised shares of MediWound from a “strong sell” rating to a “sell” rating in a report on Saturday, May 30th. HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of MediWound in a report on Thursday, May 28th. Finally, Oppenheimer reissued an “outperform” rating and issued a $32.00 price objective (down from $33.00) on shares of MediWound in a report on Wednesday, May 27th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, MediWound presently has a consensus rating of “Hold” and an average price target of $34.00.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.